Federal Food and Drug Administration researchers are using taxpayer funds to study whooping cough by infecting baboons in Maryland labs, aiming to fix gaps in current vaccines.
Story Highlights
- Federal Food and Drug Administration scientists say baboons mirror human whooping cough, including cough and spread.
- Studies found vaccinated baboons stayed healthy but still carried and spread the bacteria.
- Agency materials show ongoing, approved protocols for baboon pertussis research.
- Research seeks better vaccines and may inform guidance on stopping transmission.
What The Federal Food and Drug Administration Is Doing And Why It Matters
Federal Food and Drug Administration (FDA) scientists use a baboon model to study pertussis, also called whooping cough, because it copies key human features like coughing and transmission. Researchers argue that this model helps answer questions human trials cannot, such as how well vaccines block colonization and spread. The work focuses on protecting infants and reducing outbreaks. The central claim is utility: baboons get sick and spread the germ in ways similar to people, which makes results more useful.
FDA-affiliated papers report a striking pattern. Acellular vaccines kept baboons from classic symptoms, but the animals still carried high levels of bacteria and passed it to others. That finding helps explain why whooping cough can persist even in vaccinated groups. It shifts the target from only preventing disease to also stopping silent spread. The research team says the model lets them test vaccine choices and dosing in a controlled way before moving to people.
What The Record Shows About An Ongoing Program
FDA materials point to an established, continuing line of baboon research, not a one-off purchase. A 2018 FDA page cites results “demonstrated in a baboon model,” including how maternal vaccination can protect infant baboons. An internal meeting summary lists an approved support protocol comparing baboon responses to infection after different pertussis vaccines, with a named protocol number and status “Approved”. These items show formal review and ongoing oversight inside the agency’s research centers.
Earlier foundational work described the baboon as the first animal model to recapitulate the full spectrum of human pertussis, including coughing and transmission. That claim underpins later studies that compare vaccine types and explore immune responses. The core goal is to evaluate licensed vaccines and to design better ones that can block both disease and spread. The model’s value is highest where human challenge studies are not feasible or ethical, especially in infants.
How The Findings Connect To Public Health Decisions
FDA-linked studies suggest a reason for stubborn outbreaks. Vaccines can keep you from getting very sick but might not stop you from carrying and spreading the bacteria. Public health leaders want tools that cut transmission, especially to newborns. The baboon model helps test new vaccines, boosters, and maternal strategies. FDA materials say this work can inform how to improve vaccine design and use, including timing and components aimed at blocking colonization.
This research sits in a broader debate about animal use and necessity. The public record here strongly supports scientific utility, but it does not include purchase contracts or a head-to-head review of non-animal alternatives for this specific project. Agency summaries cite approvals and protocols, yet they do not disclose the vendor, price, or number and age of animals. Those are procurement details that sit outside the published science and would require separate document releases.
Sources:
thegatewaypundit.com, pmc.ncbi.nlm.nih.gov, fda.report, pubmed.ncbi.nlm.nih.gov
